These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 20647274)

  • 1. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study.
    Tam LS; Li EK; Shang Q; Tomlinson B; Li M; Leung YY; Kuan WP; Kwok LW; Li TK; Zhu Y; Kun EW; Yip G; Yu CM
    Ann Rheum Dis; 2011 Apr; 70(4):705-6. PubMed ID: 20647274
    [No Abstract]   [Full Text] [Related]  

  • 2. Cutaneous leishmaniasis in a patient with psoriatic arthritis treated with tumour necrosis factor-α inhibitor.
    Morsing NV; Andreasen CM; Rasmussen TA; Moll LT
    Scand J Rheumatol; 2024 Mar; 53(2):158-159. PubMed ID: 38275137
    [No Abstract]   [Full Text] [Related]  

  • 3. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.
    Ahlehoff O; Gislason GH; Charlot M; Jørgensen CH; Lindhardsen J; Olesen JB; Abildstrøm SZ; Skov L; Torp-Pedersen C; Hansen PR
    J Intern Med; 2011 Aug; 270(2):147-57. PubMed ID: 21114692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease.
    Eder L; Joshi AA; Dey AK; Cook R; Siegel EL; Gladman DD; Mehta NN
    Arthritis Rheumatol; 2018 Mar; 70(3):408-416. PubMed ID: 29088580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.
    Di Minno MN; Iervolino S; Peluso R; Scarpa R; Di Minno G;
    Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):705-12. PubMed ID: 21212403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate and high disease activity levels increase the risk of subclinical atherosclerosis progression in early rheumatoid arthritis: a 5-year prospective study.
    Meng H; Cheng IT; Yan BPY; Lee AP; So H; Tam LS
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38199848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction.
    Fragoulis GE; Soulaidopoulos S; Sfikakis PP; Dimitroulas T; D Kitas G
    J Inflamm Res; 2021; 14():1915-1931. PubMed ID: 34017189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis.
    Yuan Y; Yang J; Zhang X; Han R; Chen M; Hu X; Ma Y; Wu M; Wang M; Xu S; Pan F
    J Atheroscler Thromb; 2019 Mar; 26(3):260-271. PubMed ID: 30089757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis.
    Puig L
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiometabolic Disorders in Psoriatic Disease.
    Sobchak C; Eder L
    Curr Rheumatol Rep; 2017 Aug; 19(10):63. PubMed ID: 28844116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Stroke in Rheumatoid Arthritis.
    Zha AM; Di Napoli M; Behrouz R
    Curr Neurol Neurosci Rep; 2015 Dec; 15(12):77. PubMed ID: 26486791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atherosclerosis in psoriatic disease: latest evidence and clinical implications.
    Eder L; Gladman DD
    Ther Adv Musculoskelet Dis; 2015 Oct; 7(5):187-95. PubMed ID: 26425147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making the next steps in psoriatic arthritis management: current status and future directions.
    Sritheran D; Leung YY
    Ther Adv Musculoskelet Dis; 2015 Oct; 7(5):173-86. PubMed ID: 26425146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOCUS ON PSORIASIS: A REPORT FROM THE 73RD ANNUAL MEETING OF THE AMERICAN ACADEMY OF DERMATOLOGYPsoriasis-related topics included targeted therapies, safety of biologies, comorbidities.
    Donigan JM
    J Clin Aesthet Dermatol; 2015 Jul; 8(7 Suppl 3):8-16. PubMed ID: 26240675
    [No Abstract]   [Full Text] [Related]  

  • 15. Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity.
    Yilmazer B; Sahin T; Unlu BÖ; Kir HM; Cefle A
    Rheumatol Int; 2015 Aug; 35(8):1385-92. PubMed ID: 25669439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does treatment of psoriasis reduce the risk of cardiovascular disease?
    Churton S; Brown L; Shin TM; Korman NJ
    Drugs; 2014 Feb; 74(2):169-82. PubMed ID: 24420963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.
    Di Minno MN; Peluso R; Iervolino S; Lupoli R; Russolillo A; Tarantino G; Scarpa R
    Arthritis Res Ther; 2012 Oct; 14(5):R211. PubMed ID: 23036698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk in patients with psoriatic arthritis.
    Zhu TY; Li EK; Tam LS
    Int J Rheumatol; 2012; 2012():714321. PubMed ID: 22645614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Psoriatic arthritis : a permanent challenge for rheumatologists and patients--Part 1: epidemiology, pathogenesis and clinical course].
    Finzel S; Englbrecht M
    Z Rheumatol; 2011 Oct; 70(8):685-97. PubMed ID: 21912984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The perspective on psoriatic arthritis in Asia.
    Leung YY; Tam LS; Li EK
    Curr Rheumatol Rep; 2011 Aug; 13(4):369-75. PubMed ID: 21553000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.